{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:53:16Z","timestamp":1792842796998,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK078244"],"award-info":[{"award-number":["DK078244"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK082753"],"award-info":[{"award-number":["DK082753"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI149431"],"award-info":[{"award-number":["AI149431"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK134489"],"award-info":[{"award-number":["DK134489"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008333","name":"The University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011531","name":"University of Alabama","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1053\/j.ajkd.2025.09.029","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T17:08:54Z","timestamp":1772730534000},"page":"709-715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy"],"prefix":"10.1053","volume":"87","author":[{"given":"Colin","family":"Reily","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana V.","family":"Rizk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.ajkd.2025.09.029_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.semnephrol.2025.151568","article-title":"The pathology of iga nephropathy: how can it inform management?","volume":"44","author":"Haas","year":"2024","journal-title":"Semin Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.09.029_bib2","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ajkd.2025.09.029_bib3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"issue":"5","key":"10.1053\/j.ajkd.2025.09.029_bib4","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.immuni.2016.04.019","article-title":"The TNF receptor superfamily in co-stimulating and co-inhibitory responses","volume":"44","author":"Ward-Kavanagh","year":"2016","journal-title":"Immunity"},{"issue":"26","key":"10.1053\/j.ajkd.2025.09.029_bib5","doi-asserted-by":"crossref","first-page":"16330","DOI":"10.1074\/jbc.M115.661405","article-title":"Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties","volume":"290","author":"Schuepbach-Mallepell","year":"2015","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.029_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd1982","article-title":"An APRIL to remember: novel TNF ligands as therapeutic targets","volume":"5","author":"Dillon","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1053\/j.ajkd.2025.09.029_bib7","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.4049\/jimmunol.169.8.4314","article-title":"BLYS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases","volume":"169","author":"Roschke","year":"2002","journal-title":"J Immunol"},{"issue":"511","key":"10.1053\/j.ajkd.2025.09.029_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aao4910","article-title":"Structural principles of tumor necrosis factor superfamily signaling","volume":"11","author":"Vanamee","year":"2018","journal-title":"Sci Signal"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.029_bib9","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.4049\/jimmunol.0804324","article-title":"Secondary lymphoid organs: responding to genetic and environmental cues in ontogeny and the immune response","volume":"183","author":"Ruddle","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.029_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.it.2024.01.006","article-title":"Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity","volume":"45","author":"Bemark","year":"2024","journal-title":"Trends Immunol"},{"issue":"8","key":"10.1053\/j.ajkd.2025.09.029_bib11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41581-023-00706-z","article-title":"The roles of tertiary lymphoid structures in chronic diseases","volume":"19","author":"Sato","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.029_bib12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/physrev.00045.2017","article-title":"The TNF family of ligands and receptors: communication modules in the immune system and beyond","volume":"99","author":"Dostert","year":"2019","journal-title":"Physiol Rev"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.029_bib13","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfae173","article-title":"IgA class-switched CD27-CD21+ B cells in IgA nephropathy","volume":"40","author":"Popova","year":"2025","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.029_bib14","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.029_bib15","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clim.2007.11.003","article-title":"Increase in B-cell-activation factor (BAFF) and IFN-gamma productions by tonsillar mononuclear cells stimulated with deoxycytidyl-deoxyguanosine oligodeoxynucleotides (CPG-ODN) in patients with IgA nephropathy","volume":"126","author":"Goto","year":"2008","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.029_bib16","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1681\/ASN.2016050496","article-title":"Toll-like receptor 9 stimulation induces aberrant expression of a proliferation-inducing ligand by tonsillar germinal center B cells in IgA nephropathy","volume":"28","author":"Muto","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ajkd.2025.09.029_bib17","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1053\/j.ajkd.2025.09.029_bib18","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.029_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cellimm.2006.08.002","article-title":"BAFF induces a hyper-IgA syndrome in the intestinal lamina propria concomitant with IgA deposition in the kidney independent of light","volume":"241","author":"McCarthy","year":"2006","journal-title":"Cell Immunol"},{"issue":"5","key":"10.1053\/j.ajkd.2025.09.029_bib20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141289","article-title":"Immunoglobulin A nephropathy is characterized by anticommensal humoral immune responses","volume":"7","author":"Currie","year":"2022","journal-title":"JCI Insight"},{"issue":"11","key":"10.1053\/j.ajkd.2025.09.029_bib21","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.0307348101","article-title":"Impaired IgA class switching in APRIL-deficient mice","volume":"101","author":"Castigli","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.029_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"issue":"9","key":"10.1053\/j.ajkd.2025.09.029_bib23","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/ndt\/gfaa344","article-title":"High levels of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients","volume":"36","author":"Sallustio","year":"2021","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.029_bib24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.029_bib25","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3892\/mmr.2014.2359","article-title":"TLR9 and BAFF: Their expression in patients with IgA nephropathy","volume":"10","author":"Li","year":"2014","journal-title":"Mol Med Rep"},{"issue":"11","key":"10.1053\/j.ajkd.2025.09.029_bib26","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ng.3118","article-title":"Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens","volume":"46","author":"Kiryluk","year":"2014","journal-title":"Nat Genet"},{"issue":"2","key":"10.1053\/j.ajkd.2025.09.029_bib27","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.1047","article-title":"A genome-wide association study in Han Chinese identifies multiple susceptibility loci for IgA nephropathy","volume":"44","author":"Yu","year":"2012","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.029_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.09.029_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"issue":"2-suppl","key":"10.1053\/j.ajkd.2025.09.029_bib30","doi-asserted-by":"crossref","first-page":"S769","DOI":"10.1016\/j.ekir.2024.11.1357","article-title":"Wcn25-1585 a phase 1\/2 trial of zigakibart in IgA nephropathy (IgAN)","volume":"10","author":"Barratt","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2025.09.029_bib31","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2025.09.029_bib32","doi-asserted-by":"crossref","unstructured":"Lafayette R. Long-term atacicept shows continued benefit in IgA nephropathy [abstract]. Presented at: 2024 Conference of the European Renal Association; May 23-26; Stockholm, Sweden. doi:10.55788\/ad86bcd0.","DOI":"10.55788\/ad86bcd0"},{"issue":"3","key":"10.1053\/j.ajkd.2025.09.029_bib33","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2025.09.029_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ekir.2024.01.003","article-title":"Effect of telitacicept on circulating Gd-IgA1 and IgA-containing immune complexes in IgA nephropathy","volume":"9","author":"Zan","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:55:33Z","timestamp":1778086533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626007298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0272638626007298"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.09.029","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}